arrow
T

Toshihiko Yokoyama

Institute for Molecular Science
H指数:53
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Favorable clinical impact of histological subtype with non-small cell carcinoma-not otherwise specified in patients with non-small cell lung cancer receiving immune checkpoint inhibitors

非小细胞肺癌患者接受免疫检查点抑制剂治疗时,组织学亚型对非小细胞癌(未特指)的积极临床影响

2026-02-010
OAAI
Skin disorder within 30 days is a favorable prognostic factor in patients with lung squamous cell carcinoma treated with necitumumab plus gemcitabine and cisplatin: a sub-analysis of the NINJA study

30天内出现皮肤疾病是接受尼妥珠单抗联合吉西他滨和顺铂治疗的肺鳞状细胞癌患者的有利预后因素:NINJA研究的亚组分析

2025-03-150
OA
Clinical impact of hypomagnesemia induced by necitumumab plus cisplatin and gemcitabine treatment in patients with advanced lung squamous cell carcinoma: a subanalysis of the NINJA study

尼妥珠单抗联合顺铂和吉西他滨治疗在晚期肺鳞状细胞癌患者中诱导低镁血症的临床影响:NINJA研究的亚组分析

2025-02-140
OA
Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study
2023-12-014
OA
A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903

来自实际数据集的奥希替尼与阿法替尼作为EGFR突变的非小细胞肺癌一线治疗的多中心队列研究: CJLSG1903

2021-06-0135
OAAI
Femtosecond Charge Density Modulations in Photoexcited CuWO4
2021-03-267
OAAI
A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19

新型冠状病毒肺炎住院患者早期与晚期Favipiravir治疗的前瞻性,随机,开放标签试验

2020-11-17176
OAAI
Emergence of Oxygen Reduction Activity in Zirconium Oxide-Based Compounds in Acidic Media: Creation of Active Sites for the Oxygen Reduction Reaction
2019-07-0833
PREAI